INTRODUCTION AND OBJECTIVES: Patient and disease characteristics influence ureteric stricture management with DJ stents, metallic stents, endoscopic, or reconstructive surgery. Memokaths are an option with reported 90-100% patency and 14-30% complication rates, but the published literature is limited by small sample size and short follow-up duration up to 22 months. Objective: To independently analyse 5-year Memokath stent outcomes, identifying variables associated with good outcomes to update clinical guidelines.
INTRODUCTION AND OBJECTIVES: Patient and disease characteristics influence ureteric stricture management with DJ stents, metallic stents, endoscopic, or reconstructive surgery. Memokaths are an option with reported 90-100% patency and 14-30% complication rates, but the published literature is limited by small sample size and short follow-up duration up to 22 months. Objective: To independently analyse 5-year Memokath stent outcomes, identifying variables associated with good outcomes to update clinical guidelines.
METHODS: Management of obstructed ureteric stricture patients with Memokath stents was reviewed independently using electronic patient records. Outcomes included time to first complication, complications' incidence and severity. Multiple linear regression was performed identifying variables linked with particular outcomes.
RESULTS: 100 patients aged 23-87 years (mean 57) received Memokath stents for ureteric obstruction, 59% for malignant strictures, with 20% bilateral. Only 25 patients had no complications: either alive with, or dying of their primary malignancy with their original Memokath. Median time to complication in the remaining 75 patients was 12.5 months with Memokaths lasting longer in patients with malignancy (p¼0.02). Multiple linear regression analyses showed that increased eGFR (p¼0.005) and age (p¼0.0001) independently significantly predicted greater Memokath lifespan, while co-morbidities, stricture length and location, and underlying pathology, did not. 5 year outcomes: 25 patients had a Memokath in situ: 14 still alive with the original. 22 had other stents, while 12 required major surgery. 66% of patients with most severe complications (need for major surgery or dialysis) were in the benign group.
CONCLUSIONS: Memokaths are a reasonable option for patients with malignant ureteric obstruction and life expectancy up to 1 year. Age and eGFR greater than 45 predicted longer Memokath duration. Patient and stricture variables other than aetiology did not affect Memokath durability, but should be considered for delivery of the most appropriate patient-centred individualised care. 5 year complication rates were significantly higher than previously reported (75 vs 25%). Updated practice guidelines would aid future patient selection and counselling, as well as encouraging protocolled follow-up and patient reported outcomes assessment, when considering metallic stent drainage for ureteric obstruction. METHODS: This randomized controlled trial included 135 patients who were treated with BMGU between 2014 and 2015. The buccal mucosa graft was harvested from the inner cheek. Following computer-based randomization, 63 and 72 patients received C and NC of the donor site. Preoperatively, at postoperative day (POD) one, 5, 21 as well as 3 and 6 months postoperatively, patients completed standardized questionnaires. The intensity of oral pain and of the perineogenital region, respectively, was assessed with a numeric rating scale (NRS). The quality of oral pain was evaluated using the Short-Form McGill Pain Questionnaire (SF-MPQ), consisting of a sensory and affective pain subscale. The co-primary endpoints were intensity and quality of oral pain. Secondary endpoints included oral morbidity as well as intensity of pain of the perineogenital region. Generalized linear mixed models evaluated the effect of C versus NC on intensity and quality of oral pain, oral morbidity as well as intensity of pain of the perineogenital region.
RESULTS: Oral pain intensity mean scores on the NRS were 0.15 (standard deviation (SD): 0.531; range: 0-3), 3.16 (SD: 2.10; range: 0-10), 2.89 (SD: 2.16; range: 0-9), 1.30 (SD: 1.72; range: 0-8), 1.00 (SD: 1.42; range: 0-6) and 0.77 (SD: 1.33; range: 0-6), respectively, at baseline, POD one, 5, 21 as well as 3 and 6 months. The most frequent sensory dimension of pain was 0 tender 0 . The most common affective dimension of pain was 0 tiring-exhausting 0 on POD one, 5 and 3 months. On POD 21 and 6 months, the most frequent affective pain was 0 fearful 0 . Oral morbidity and complications included pain, bleeding, swelling, numbness, alteration of salivation and taste, as well as impairment of mouth opening, smiling, diet and speech. C versus NC of the donor site had no effect on intensity and quality of oral pain as well as morbidity and complications. Time from BMGU and length of buccal mucosa graft had significant effects on intensity and quality of oral pain (p-values<0.042). Mean NRS cores of the pain intensity of the perineogenital region were 0.86 (SD: 1.74; range: 0-8), 3.94 (SD: 2.24; range: 0-10), 2.70 (SD: 2.08; range: 0-8), 1.81 (SD: 1.63; range: 0-8), 1.37 (SD: 1.71; range: 0-8) and 1.18 (SD: 1.76; range: 0-7), respectively, at baseline, POD one, 5, 21 as well as 3 and 6 months. C versus NC had no effect on intensity of pain of the perineogenital region. Time from BMGU, length of the buccal mucosa graft and perioperative analgesic medication had significant effects on the intensity of pain of the perineogenital region (p-values<0.035).
CONCLUSIONS: In conclusion, C versus NC of the donor site has no effect on intensity and quality of oral pain, morbidity and complications. Both, C and NC of the buccal mucosa harvest site, are feasible and safe procedures.
Source of Funding: None

PD60-11 POPULATION-BASED MANAGEMENT OF MALE URETHRAL STRICTURE DISEASE
Robert Goldfarb*, Steven Brandes, New York, NY; Peter Kirk, Tudor Borza, Yongmei Qin, Ted Skolarus, Ann Arbor, MI INTRODUCTION AND OBJECTIVES: Male urethral stricture disease is a common condition with significant quality of life and economic implications. While endoscopic treatment with incision or dilation is the most common treatment approach, the AUA guidelines (www.auanet.org/guidelines) recommend urethroplasty based on increased long-term success rates. However, the extent to which this procedure is performed relative to endoscopic treatment in real-world practice in the USA is unknown. Thus, we conducted a populationbased study of patients treated for urethral stricture disease to examine management patterns and opportunities for improvement.
METHODS: We identified male patients who underwent procedures for urethral stricture disease between 2001 and June 2015 based on ICD-9 codes and administrative claims from a large, national US health insurer (Clinformatics TM Data Mart Database, Optum Insight, Eden Prairie, MN). We assessed utilization and standardized cost of endoscopic treatments (urethrotomy and dilation) and urethroplasty. We examined patient factors associated with endoscopic treatment versus urethroplasty using multivariable logistic regression.
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